Novartis AG Long Term Debt 2010-2023 | NVS

Novartis AG long term debt from 2010 to 2023. Long term debt can be defined as the sum of all long term debt fields.
  • Novartis AG long term debt for the quarter ending December 31, 2023 was $18.436B, a 8.93% decline year-over-year.
  • Novartis AG long term debt for 2023 was $18.436B, a 8.93% decline from 2022.
  • Novartis AG long term debt for 2022 was $20.244B, a 11.61% decline from 2021.
  • Novartis AG long term debt for 2021 was $22.902B, a 12.78% decline from 2020.
Novartis AG Annual Long Term Debt
(Millions of US $)
2023 $18,436
2022 $20,244
2021 $22,902
2020 $26,259
2019 $20,353
2018 $22,470
2017 $23,224
2016 $17,897
2015 $16,327
2014 $13,799
2013 $11,242
2012 $13,781
2011 $13,855
2010 $14,360
2009 $8,675
Novartis AG Quarterly Long Term Debt
(Millions of US $)
2023-12-31 $18,436
2023-09-30 $18,068
2023-06-30 $18,259
2023-03-31 $20,396
2022-12-31 $20,244
2022-09-30 $19,732
2022-06-30 $22,232
2022-03-31 $22,796
2021-12-31 $22,902
2021-09-30 $23,101
2021-06-30 $24,828
2021-03-31 $25,747
2020-12-31 $26,259
2020-09-30 $26,497
2020-06-30 $23,955
2020-03-31 $23,800
2019-12-31 $20,353
2019-09-30 $20,131
2019-06-30 $20,364
2019-03-31 $21,225
2018-12-31 $22,470
2018-09-30 $22,605
2018-06-30 $22,760
2018-03-31 $23,199
2017-12-31 $23,224
2017-09-30 $23,163
2017-06-30 $22,999
2017-03-31 $22,933
2016-12-31 $17,897
2016-09-30 $18,259
2016-06-30 $16,276
2016-03-31 $16,465
2015-12-31 $16,327
2015-09-30 $13,412
2015-06-30 $13,301
2015-03-31 $14,834
2014-12-31 $13,799
2014-09-30 $12,670
2014-06-30 $12,874
2014-03-31 $15,202
2013-12-31 $11,242
2013-09-30 $11,119
2013-06-30 $11,615
2013-03-31 $11,610
2012-12-31 $13,781
2012-09-30 $15,823
2012-06-30 $13,754
2012-03-31 $13,896
2011-12-31 $13,855
2011-09-30 $13,738
2011-06-30 $13,924
2011-03-31 $14,532
2010-12-31 $14,360
2010-09-30 $14,331
2010-06-30 $13,235
2010-03-31 $13,445
2009-12-31 $8,675
2009-09-30 $8,706
2009-06-30 $9,196
2009-03-31 $6,978
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $209.653B $45.440B
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $731.812B 105.77
Novo Nordisk (NVO) Denmark $591.861B 45.48
Johnson & Johnson (JNJ) United States $372.169B 14.78
Merck (MRK) United States $332.279B 60.46
AbbVie (ABBV) United States $293.876B 15.18
AstraZeneca (AZN) United Kingdom $238.424B 20.73
Pfizer (PFE) United States $162.291B 20.17
Sanofi (SNY) $123.116B 11.62
Innoviva (INVA) United States $0.998B 7.01